Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

• Автори: Chan Zou (Автор), Xiaocong Zuo (Автор), Jie Huang (Автор), Ye Hua (Автор), Shuang Yang (Автор), Xiaoyan Yang (Автор), Can Guo (Автор), Hongyi Tan (Автор), Jun Chen (Автор), Zhaoxing Chu (Автор), Qi Pei (Автор), Guoping Yang (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2019-10-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Background and Objective: Inhibition of thrombosis and platelet aggregation through a thromboxane synthetase inhibitor proved to be an effective and promising treatment for cardiovascular and/or cerebrovascular disease (CCVD) patients. This phase I study evaluated the safety, tolerability, and pharm...